Clinical Trial Update: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial of imatinib mesylate in patients with Stage III or Stage IV ovarian epithelial cancer or primary peritoneal cancer has completed. The study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED